Matrifen
Drugas defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
NCT Number: NCT00556270
The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
"Nycomed Deutschland GmbH", Aachen, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Main inclusion criteria:
Main exclusion criteria:
as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
Time frame: within 1 month
Time frame: within 1 month
Nycomed
Industry
Matrifen for Therapy of Severe, Chronic Pain.
Acronym: MATRIX II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07335159
Acute Pain, Agnosia
Tallahassee, Florida, United States
View Trial DetailsNCT06062108
Acute Pain, Chronic Pain
Draguignan, Var, France
View Trial DetailsNCT01178164
Brain Diseases, Brain Diseases, Metabolic
Bordeaux, France
View Trial DetailsNCT03974191
Back Pain, Behavior
Alingsås, Sweden
View Trial Details